These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15485608)

  • 1. Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story.
    Meagher EA
    Curr Cardiol Rep; 2004 Nov; 6(6):457-63. PubMed ID: 15485608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality.
    Pirillo A; Norata GD; Catapano AL
    Curr Pharm Des; 2013; 19(21):3841-57. PubMed ID: 23286430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Brown BG; Zhao XQ
    Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
    Knopp RH; Paramsothy P; Atkinson B; Dowdy A
    Am J Cardiol; 2008 Apr; 101(8A):48B-57B. PubMed ID: 18375242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid.
    Schachter M
    Cardiovasc Drugs Ther; 2005 Dec; 19(6):415-22. PubMed ID: 16453091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?
    Rana JS; Boekholdt SM
    Curr Opin Cardiol; 2010 Nov; 25(6):622-6. PubMed ID: 20852414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
    Hausenloy DJ; Yellon DM
    Curr Opin Cardiol; 2009 Sep; 24(5):473-82. PubMed ID: 19574922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies on HDL: should it be a target biomarker in patients with lipid disorders?
    Nicholls SJ; Andrews J; Duong M
    Curr Vasc Pharmacol; 2014; 12(4):649-52. PubMed ID: 23627977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.
    Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS
    J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriate clinical use of statins: a discussion of the evidence, scope, benefits, and risk.
    Perlmutter D; Golomb B; Sinatra S; Campbell AW
    Altern Ther Health Med; 2013; 19 Suppl 1():14-25. PubMed ID: 23981463
    [No Abstract]   [Full Text] [Related]  

  • 18. Researchers still seek clinical benefit in raising levels of good cholesterol.
    Mitka M
    JAMA; 2012 Jan; 307(1):21-2. PubMed ID: 22215155
    [No Abstract]   [Full Text] [Related]  

  • 19. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
    Goumas GS
    Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.